OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
This article was originally published in The Pink Sheet Daily
Executive Summary
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
You may also be interested in...
Purdue Pharma: From Blockbuster Success To Bankrupt Villain
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
Opana Withdrawal Request Builds On US FDA Actions On Palladone, OxyContin
Earlier withdrawals of Purdue’s Palladone and original OxyContin create precedent for request that Endo’s Opana ER come off market due to risk of abuse; former chief counsel sees agency's move as ‘tip of the iceberg’ on opioid safety actions.
Purdue Abuse Study May Create Ongoing Challenge For Generic Entry
OxyContin’s three-year data exclusivity for study of intranasal liking might be just the beginning of labeling hurdles for ANDAs.